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Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple intracellular processes
including DNA replication, mitosis, and stress response. Plk1, the most well understood family member, regulates
numerous stages of mitosis and is overexpressed in many cancers. Plk inhibitors are currently under clinical
investigation, including phase III trials of volasertib, a Plk inhibitor, in acute myeloid leukemia and rigosertib, a dual
inhibitor of Plk1/phosphoinositide 3-kinase signaling pathways, in myelodysplastic syndrome. Other Plk inhibitors,
including the Plk1 inhibitors GSK461364A, TKM-080301, GW843682, purpurogallin, and poloxin and the Plk4
inhibitor CFI-400945 fumarate, are in earlier clinical development. This review discusses the biologic roles of Plks
in cell cycle progression and cancer, and the mechanisms of action of Plk inhibitors currently in development
as cancer therapies.
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During the cell cycle, diverse molecular signals are integrated to
initiate and maintain checkpoints that halt the progression of cell
growth and allow time for DNA repair [1]. These checkpoints, which
occur at the G1/S phase transition, the G2/M phase transition, and
during mitosis before cell division, are tightly regulated by nuclear
serine-threonine kinases, including cyclin-dependent kinases (Cdks),
Polo-like kinases (Plks), and Aurora kinases [2]. In cancer, these
kinases are often dysregulated, promoting uncontrolled cell prolifer-
ation and aberrant cell division [1]. Dysregulated expression of
different Plk family members has been documented in many cancer
types and has been associated with poor prognosis, leading to an
enhanced interest in these kinases as promising targets for anticancer
drug development [3]. This review will discuss the functions of the
Plk family members in cell cycle progression and their dysregulation
in cancer. The mechanisms of action and preclinical findings of
promising Plk inhibitors, some of which are now in clinical trials, will
also be discussed.
Structure of Plks
The Polo gene was first cloned from Drosophila melanogaster in 1988,
and it was observed that mutations in Polo induced abnormal spindle
poles during mitoses [4]. Five mammalian homologues for Polo,
named Plk1 to Plk5, were soon identified and have been reviewed
by Strebhardt [3]. The Plk1 to Plk4 proteins have similar structures,
with a conserved serine-threonine kinase domain located at the
amino-terminal and a regulatory domain consisting of one (as in Plk4)or two (as in Plk1 to Plk3) polo-box domains (PBDs) at the
carboxyl-terminal (Figure 1) [5]. Crystal structures of the kinase and
PBDs of human Plk1 are displayed in Figure 2. PBD-dependent
binding is important for subcellular localization and targeting of Plk
activity toward specific subcellular domains [6]. Distinct from the other
Plk family members, Plk5 is a PBD-containing protein that lacks the
kinase domain [7].
Functions of Plks in the Cell Cycle
Plk1 is expressed in normal dividing cells and has a pivotal role in
regulating many key stages of the cell cycle [3]. In mouse models,
homozygous loss of Plk1 resulted in early embryonic lethality, with
Figure 1. Domain structures of the human Plk family of proteins. Open reading frame amino acid (aa) lengths are shown on the right, and
positions of the kinase domains (red) and polo-boxes 1 and 2 (blue) are indicated. Nuclear localization (NLS) sequences are indicated in
green, and the D-box domain is indicated in yellow. Residues that are critical for ATP-binding and enzymatic activation (T-loop) within the
kinase domains and phospho-selectivity within the polo-boxes are indicated. Adapted by permission from Macmillan Publishers Ltd,
copyright (2006) [5].
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assembly at embryonic day 3.5, ultimately failing to survive past the
eight-cell stage [8]. In contrast, mice heterozygous for Plk1 (Plk1+/−)
were healthy at birth and displayed no obvious defects from the loss of
one Plk1 allele [8]. Preclinical studies in human cell lines have
demonstrated that Plk1 activity is essential in numerous stages ofmitosis,
including functional maturation of centrosomes and bipolar spindle
assembly, M phase entry, nuclear envelope breakdown (NEBD), sister
chromatid cohesion and formation of kinetochore-microtubule attach-
ments, and finally mitotic exit and cytokinesis (Figure 3) [5].
Early studies in human immortalized HeLa cells demonstrated the
requirement of Plk1 activity in centrosome maturation and
establishment of a bipolar spindle before mitotic entry [9].
Microinjection of anti-Plk1 antibodies into cells resulted in reduced
centrosome size and decreased accumulation of γ-tubulin, now
known to form the γ-tubulin ring complex required for microtubule
nucleation. Later studies further demonstrated that Plk1 phosphorylation
of the centrosome-associated ninein-like protein, involved in
microtubule assembly, first dissociates ninein-like protein from the
centrosome, allowing recruitment of the γ-tubulin ring complex
(Figure 3) [10]. Using RNA interference (RNAi) in human
osteosarcoma cell lines, Plk1 was also shown to regulate the
centrosomal localization of Aurora A kinase, another key regulator
of centrosome maturation and function [11].Plk1 is part of a regulatory network controlling Cdk1/cyclin B
complex activity and entry into mitosis at the G2/M transition [2].
Before active complex formation with cyclins, Cdk activation requires
the removal of inhibitory phosphates by Cdc25 phosphatases.
Preclinical studies in human Jurkat cells have shown that Plk1
directly phosphorylates and activates Cdc25, resulting in subsequent
dephosphorylation of the inactive Cdk1/cyclin B complex [12].
Further, Plk1 was shown to phosphorylate and stimulate degradation
of Wee1, a negative regulator of Cdk1 (Figure 3) [13]. Plk1-mediated
degradationofWee1was also shown tobe an important step in the regulation
of mitotic entry following DNA damage response, suggesting an important
role for Plk1 in DNA damage recovery following G2 phase arrest [13].
Another essential step for mitotic entry that occurs during G2/M
transition is NEBD, a process regulated by both microtubules and
microtubule-associated motor proteins, such as the dynein/dynactin
complex [14]. In recent studies in mammalian cells, Plk1 was shown
to interact with and phosphorylate p150Glued, a major component of
the dynein/dynactin complex, during NEBD at prophase [14]. This
Plk1-mediated phosphorylation of p150Glued positively regulated the
accumulation of p150Glued at the nuclear envelope (Figure 3).
Further, expression of a Plk1-unphosphorylatable mutant of
p150Glued (p150Glued-S179A) resulted in reduced NEBD and G2
phase arrest, suggesting that Plk1 phosphorylation of p150Glued may
be an important regulatory step of NEBD and mitotic entry [14].
Figure 2. Crystal structure of the N-terminal kinase domain (a) and C-terminal PBD (b) and (c) of human Plk1. (a) The crystal structure of
the kinase domain was determined in complex with the pyrrolo-pyrazole inhibitor PHA 680626 at 2.4-Å resolution. The N-terminal and
C-terminal extensions are shown in orange, and the activation loop is shown in green. The regulatory phosphorylation site Thr210 was
mutated to Val210 to reduce conformational heterogeneity. The position of Ser137, which has been proposed as an additional
phosphorylation site for the activation of the kinase activity of Plk1, is also indicated. (b) The crystal structure of the PBD is shown as a
ribbon diagram from two different angles in complex with a phosphothreonine-containing peptide (shown in yellow). Polo-box 1 and
polo-box 2 are shown in red and purple, respectively. The polo-cap at the N-terminal end of polo-box 1 (gray) folds around polo-box 2,
tethering it to polo-box 1 and forming a pocket to accommodate the phosphopeptide. (c) A superposition of the polo-box 1 and polo-box 2
structures is shown (colors indicated in b). Each polo-box consists of a six-stranded β-sheet and an α-helix, which associate to form a
12-stranded β-sandwich domain. This structure documents an interaction along a positively charged cleft formed between the two
polo-boxes. Reprinted with permission from Macmillan Publishers Ltd, copyright (2010) [3].
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chromatids at anaphase requires the dissociation of cohesin complexes
from the replicated chromosomes and the formation of kinetochor-
e-microtubule attachments. In a Xenopus model, Plk1 was shown to
phosphorylate the SA2 subunit of cohesin, resulting in dissociation of
the cohesin complex from chromosomes during prophase [15]. In
addition, recruitment of Plk1 to kinetochore/centromere regions of
chromosomes has been observed, suggesting a role in kinetochor-
e-microtubule attachment [16]. In this context, Plk1 was shown to
phosphorylate CLIP-170, a protein that directly interacts with the
dynein/dynactin complex to promote kinetochore-microtubule
attachments [17]. Plk1 phosphorylation of CLIP-170 at S195 is
thought to create a docking site for additional phosphorylation by
casein kinase 2, which promotes dynactin-mediated kinetochore
localization of CLIP-170 during prometaphase (Figure 3). Inhibition
of CLIP-170 phosphorylation by Plk1 and casein kinase 2 through
mutation of the specific phosphorylation residues resulted in defects
in kinetochore formation [17]. Plk1 was also shown to phosphorylate
and regulate the localization of Sgt1, a co-chaperone of heat shock
protein 90, to kinetochores during prometaphase [18]. Plk1
phosphorylation of Sgt1 enhanced the association of heat shock
protein 90–Sgt1 with the MIS12 complex. This interaction stabilizedthe MIS12 complex at kinetochores, facilitating the recruitment of
the NDC80 complex and subsequent formation of microtubule-
binding sites at the kinetochores (Figure 3) [18]. Inhibition of Plk1
phosphorylation of Sgt1 decreased recruitment of the MIS12 and
NDC80 complexes at kinetochores and impaired microtubule
attachment, ultimately resulting in chromosome misalignment and
delayed onset of anaphase.
Complete chromosome segregation and exit from mitosis is
regulated by the anaphase-promoting complex/cyclosome (APC/C)
[19]. Along with the Cdk1/cyclin B complex, Plk1 has been shown to
phosphorylate subunits of the APC/C, jointly activating the ubiquitin
ligase activity of the APC/C that is required for degradation of mitotic
cyclins, facilitation of sister chromatid segregation, and initiation of
mitotic exit [19]. Plk1 was also shown to regulate the localization and
destruction of a negative regulator of APC/C, early mitotic inhibitor 1
[20]. In coordination with chromosome segregation, Plk1 has been
shown to localize to the central spindle [21] and regulate the assembly
of the HsCyk-4 RhoGAP/Ect2 RhoGEF complex, facilitating cleavage
furrow formation in late-stage mitosis, which is necessary for the final
stage of the cell cycle, cytokinesis (Figure 3) [22].
Multiple levels of control are in place to ensure that Plk1-dependent
phosphorylation of its various substrates is properly coordinated in time
Figure 3. Functional roles of Plk1 in cell cycle progression. The figure is a schematic diagram depicting Plk1 as a regulator of several
stages during mitotic progression. This view is not intended to be complete but represents frequently studied aspects of Plk1 activities
along with several newly ascribed functional interactions. Stimulatory interactions are shown in brown and inhibitory interactions are
shown in blue.
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factors, including forkhead box protein M1, p53, and the E2F family,
during various stages of the cell cycle [3,23]. Regulation of Plk1 protein
activity by phosphorylation on a conserved Thr residue (Thr210) in the
kinase activation loop was shown to be mediated by Bora/Aurora A
during normal mitotic entry and following DNA damage checkpoint
recovery [24]; other kinases and phosphatases have also been implicated
in the regulation of Plk1 at this residue [23]. In addition to regulation of
Plk1 activity by kinases/phosphatases, spatial regulation of Plk1 through
protein interactions with the PBD domain has been demonstrated with
numerous proteins [23]; details regarding these interactions are beyond
the scope of this review. Likemany other proteins, Plk1 is also a target of
ubiquitination and proteosome-dependent degradation, with the APC/C
as the requisite ubiquitin ligase for Plk1 at mitotic exit [25].
The functional roles of the other Plk members in normal cell
biology are not yet fully understood. Plk2, a centrosomal kinase
expressed primarily in G1 phase, has been shown to regulate centriole
duplication in cooperation with Plk4 [26] and may play a role in
the G2/M checkpoint following activation by p53 in response to
genotoxic damage [27]. Unlike Plk1 null mice (Plk1−/−) mice,Plk2−/− mice are viable, albeit with observable retardation of skeletal
development and growth [28]. Despite these developmental delays,
no differences in 12-month survival rates compared with wild-type
mice were observed.
Among the Plk family members, Plk3 appears to be most similar to
Plk2, with murine homozygous loss of Plk3 having no effect on
viability [29]. Interestingly, Plk3−/− mice displayed no obvious
growth impairment and were larger than age- and sex-matched,
wild-type littermates by 20 months of age. In human cell lines, Plk3
expression was shown to peak in G1 phase [30]. RNAi-mediated
depletion of Plk3 in these cells resulted in attenuation of cyclin E
expression and inhibition of S phase entry, suggesting a role for Plk3
in the G1/S phase transition. Plk3 was also shown to localize to
centrosomes during interphase and spindle poles during mitosis and
was detected at the midbody during cytokinesis [31]. Overexpression
of Plk3 in human cells resulted in mitotic arrest and defects in
cytokinesis. As such, Plk3 has been implicated in the regulation of
various stages of mitosis and response to genotoxic stress [31].
Similar to findings with Plk1, homozygous loss of Plk4 resulted in
embryonic lethality in mouse models [32]. Plk4−/− embryos ceased to
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appeared to be arrested in late-stage mitosis. In mammalian cell lines,
Plk4 expression was shown to increase at the G1/S phase transition,
persisting until late M phase and declining in early G1 phase [33].
The Plk4 protein has been shown to localize to the nucleolus during
G2 phase, to centrosomes during early M phase, and to the cleavage
furrow during cytokinesis [32]. In addition to the established role of
Plk4 in centriole duplication [26], Plk4 was implicated in the
regulation of APC/C-mediated destruction of cyclin B1 during
mitotic exit in Plk4−/− mouse models [32].
Plk5was cloned in2010 [34] and little is known about its functions.The
Plk5 protein lacks the kinase domain found in other Plk family members
and appears to have no catalytic activity (Figure 1). To date, the effects of
genetic deletion of Plk5 inmousemodels have yet to be reported. Inmouse
and human cell lines, ectopic expression of Plk5 resulted in a G1 phase cell
cycle arrest and subsequent apoptosis [34]. Plk5 levels were shown to be
downregulated in proliferating human cells compared with quiescent cells
[7]. Interestingly, Plk5 was shown to function in neuron biology and was
expressed primarily in brain of both mice and humans [7].
Plk Expression in Human Tumors
Cell cycle dysregulation is a common feature of human cancer, with
cancer cells frequently displaying unscheduled proliferation, as well as
genomic and chromosomal instability [1]. As Plk1 plays an important
role in cell cycle progression in normal proliferating tissues, it is not
surprising that Plk1 is overexpressed in many cancer types, including
melanoma, breast, non–small cell lung, colorectal, prostate, pancre-
atic, ovarian, and head and neck cancers, as well as non-Hodgkin’s
lymphomas and acute myeloid leukemia (AML) as reviewed by
Strebhardt [3] and Cholewa et al. [35]. In contrast to the low levels
of Plk1 expression observed during interphase in normal cells,
localization of Plk1 to the nucleus in cancer cells occurs before G2/M
phase and persists through G1/S phase [35]. Plk1 overexpression is
associated with a worse prognosis, including lower overall survival in
several cancer types, such as non–small cell lung, head and neck,
melanoma, and prostate cancers [3,35]. Interestingly, Plk1 expression
is low in surrounding normal, non-dividing tissue. No chromosomal
translocations or mutations have been found in the Plk1 gene [35].
In contrast to Plk1 overexpression observed in some human
cancers, Plk2 expression was found to be decreased in B-cell
neoplasms due to CpG methylation–dependent silencing [36].
Methylation in the Plk2 CpG island has also been observed in
other hematologic malignancies and was correlated with chemother-
apeutic sensitivity in cancer cell lines and outcome in patients with
ovarian cancer treated with platinum- and taxane-based therapy [37].
In core-binding factor AML, overexpression of the microRNA
miR-126/126*, a negative regulator of Plk2, was observed, potentially
suggesting a role for Plk2 as a tumor suppressor in these malignancies
[38]. Plk3 has also been suggested as a possible tumor suppressor since
it is often downregulated in certain tumors, such as lung and head and
neck cancers [39,40]. Expression levels of Plk4 in human cancers are
less consistent, with reported overexpression in colon and breast
cancers [41,42] and down-regulation in hepatocellular carcinoma
[18]. In breast cancer cells overexpressing Plk4, RNAi depletion of
Plk4 was shown to inhibit cell growth in vitro and in vivo [42].
Finally, Plk5 was shown to be significantly downregulated in human
brain tumors, with frequent silencing of Plk5 by hypermethylation
observed in astrocytomas and glioblastomas [7]. Re-expression of
Plk5 prevented cell proliferation of these tumor cells in vitro.Interaction of Plks with Other
Cancer-Associated Pathways
Crosstalk between Plk1 to Plk4 and the p53 tumor suppressor has
been reported in cancer cells under conditions of genotoxic stress [3].
Plk1 was also shown to be required for the viability of cells harboring
activated Ras [43] or inactivated p53, particularly in the presence of
genotoxic damage [44]. Accumulating evidence suggests an important
role for Plk1 in the negative regulation of p53 activity through two
novel Plk1 targets: G2 and S phase–expressed protein 1 (GTSE1) and
DNA topoisomerase 1 binding protein (Topors) [45,46]. GTSE1 is a
negative regulator of p53 that directly binds and shuttles p53 out of
the nucleus, inducing its degradation and allowing for G2 checkpoint
recovery [46]. Plk1 was shown to phosphorylate GTSE1 and promote
its nuclear localization, facilitating the interaction of GTSE1 with p53
and subsequent checkpoint recovery. Topors is a dual ubiquitin and
sumoylation E3 ligase for p53, wherein ubiquitination of p53 results
in its degradation but sumoylation of p53 results in increased p53
stability [45]. Plk1-mediated phosphorylation of Topors was shown
to modulate the activity of this ligase, resulting in decreased p53
sumoylation and increased p53 ubiquitination by Topors. Taken
together, these data suggest that Plk1 is an important negative regulator
of both p53 protein stability and nuclear localization [45,46].
Since the p53 tumor suppressor is a critical regulator of DNA
damage checkpoints and cell cycle control, the negative regulation of
p53 by Plk1 may provide a potential mechanism for the tumorigenic
potential of Plk1. In this context, depletion of Plk1 using small
interfering RNA in human cancer cell lines resulted in a G2/M phase
arrest and subsequent apoptosis, which was characterized by
activation of the p53 pathway [47–49]. Interestingly, the cytotoxicity
observed with Plk1 depletion was enhanced in cancer cells with either
no p53 or inactivated p53 compared with those harboring wild-type
p53 protein. DNA damage was detected in Plk1-depleted cells
regardless of p53 status, suggesting that the combined loss of Plk1 and
p53 checkpoint activity may contribute to enhanced cytotoxicity in
the presence of accumulating genotoxic damage [47,48]. Importantly,
normal cells were shown to be largely unaffected by Plk1 depletion in
these studies, supporting the feasibility of Plk1 as a potential target for
cancer therapy [47–49].
As discussed, Plks are susceptible to aberrant DNA methylation in
many tumor types. In a recent study by Ward et al., oxidative stress
induced by hypoxic conditions or reactive oxygen species (ROS) in
mouse embryonic fibroblasts resulted in significant hypermethylation
of Plk1 and Plk4 promoters and a reduction in the corresponding
protein levels [50]. In human hepatocellular carcinoma cell lines,
hypermethylation of Plk1 and Plk4 appeared to be dependent on the
presence of functional p53, and Plk4 up-regulation was observed in
p53-deficient cells in the presence of hypoxia and ROS. Plk4
expression and protein levels were also elevated in response to ROS
treatment in p53-deficient osteosarcoma cells, wherein the Plk4
promoter was observed to be hypomethylated [50]. These findings
highlight the complex and cell-specific activities of Plks and suggest a
model whereby oxidative stress may lead to epigenetic silencing of
Plks in normal and cancer cells in a p53-dependent manner.
However, in the absence of p53, enhanced expression of Plk1 and
Plk4 could promote aberrant cell cycle progression, genomic
instability, and tumorigenesis [50].
Plk2 and Plk3 were also shown to play important roles in
mediating response to genotoxic stress [3]. In preclinical studies, both
Plks have demonstrated a functional interaction with the p53
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induced in response to cellular stresses [27,51]. A p53-dependent
induction of Plk2 was shown in response to genotoxic damage in
irradiated cells, and depletion of Plk2 enhanced cell death in response
to mitotic catastrophe [27]. Plk3 was shown to phosphorylate and
activate p53 in an ataxia telangiectasia mutated–dependent manner in
response to DNA damage [51]. These studies suggest tumor
suppressive roles for Plk2 and Plk3 in response to genotoxic stress.
Preclinical Data Demonstrating Validity of Plk1 as
a Target in Cancer
The critical roles of Plk1 in cell cycle progression and response to
cellular stresses implicate this Plk family member in the development
of genomic instability and aberrant cell proliferation and survival
associated with tumorigenesis [35]. Although homozygous loss of Plk
was lethal in mouse models, Plk1+/− mice aged 50 to 70 weeks were
shown to harbor tumors in various organs, predominantly consisting
of lymphomas that had invaded the lung and liver, and lung
carcinomas [8]. As described above, preclinical studies have shown
that normal human cells are largely unaffected by loss of Plk1,
whereas Plk1 depletion promotes enhanced apoptosis in cancer cells
[49]. Depletion of Plk1 was also shown to decrease xenograft tumor
growth of human cancer cells [52]. These preclinical studies suggest
that Plk1 is both a feasible and relevant target for suppressing tumor
cell growth.
Tumors with both p53 deficiency and/or RAS mutations and high
Plk1 expression may be particularly sensitive to Plk1 inhibitors
[43,44]. In this context, cancer cells with wild-type p53 were shown
to be less sensitive to loss of Plk1 activity than p53-deficient cells [48].
In addition to its interactions with the p53 tumor suppressor
pathway, Plk1 was shown to facilitate survival in phosphatase and
tensin homologue (PTEN)–depleted prostate cancer cells [53]. Loss
of PTEN in prostate cancer cells lines was associated with increased
aneuploidy and mitotic stress, as well as an increase in Plk1
expression. This overexpression of Plk1 was shown to be required for
PTEN-depleted cells to adapt to mitotic stress for survival, and
reintroduction of PTEN activity reduced the survival dependence on
Plk1 [54]. Further, inhibition of Plk1 suppressed xenograft tumor
growth of PTEN-depleted prostate cancer cells. These preclinical
findings suggest that Plk1 could be a particularly relevant target for
cancers characterized by other cancer-associated mutations.
In addition to Plk1, heterozygous loss of Plk4 and homozygous
loss of Plk3 have been associated with spontaneous tumor
development in mice. In Plk4+/− mice aged N18 months, the
incidence of spontaneous liver and lung tumor development was
approximately 15 times greater compared with wild-type littermates
[55]. In Plk3−/− mice aged N18 months, the incidence of spontaneous
tumor development was more than six times higher compared with
wild-type littermates, with tumors reported in the lung, kidney, liver,
and uterus [29]. Plk3+/− mice were not reported to have elevated tumor
formation compared with wild-type mice in this study.Plk Inhibitors as Anticancer Therapies
Inhibition of cell proliferation and induction of apoptosis are basic
principles of anticancer therapy. Antimitotic therapy is standard for
many cancer types, but lack of selectivity is associated with adverse
effects, such as neurotoxicity and myelosuppression [3]. The key role
of Plk1 in oncogenic events gave impetus to the development of
potent and specific small molecule Plk1 inhibitors (Table 1). In thiscontext, there are two potential sites of Plk1 to target: the
adenosine-5′-triphosphate (ATP)–binding site in the kinase domain
(a classic target for the design of inhibitors of the human kinome) and
the PBD [63]. Targeting Plk1 RNA and the interaction of Plk1 with a
key binding partner are other possible approaches. Preclinical studies
with several different Plk inhibitors have been published, and some
are under clinical investigation. The majority of these inhibitors target
Plk1 but also Plk2 and Plk3 to a lesser extent. In addition, there is one
Plk4 inhibitor currently in clinical development.
Plk Inhibitors in Clinical Development
Rigosertib (ON 01910.Na). Rigosertib (ON 01910.Na) is a
non–ATP-competitive, small-molecule, dual inhibitor of the phos-
phoinositide 3-kinase (PI3K) and Plk signaling pathways [56]. In
recent preclinical studies by Reddy et al., rigosertib was shown to bind
the Ras-binding domain of Raf, resulting in the inactivation of Raf
and inhibition of the Raf-Plk1 interaction that activates Plk1
activity [64]. Rigosertib also binds to a similar Ras-binding domain
in PI3K, a signaling protein involved in the regulation of various
biologic processes, including cell cycle progression, metabolism, and
survival [65]. In human cancer cells in vitro and in xenograft tumor
models, rigosertib at a half maximal inhibitory concentration [IC50]
of 50 to 200 nM resulted in mitotic arrest, characterized by spindle
abnormalities and subsequent apoptosis [56]. In vivo studies in rats
and dogs to examine the safety profile of rigosertib showed that this
agent was not associated with hematotoxicity, liver damage, or
neurotoxicity [56]. Phase I studies have been completed in patients
with various tumor types, and rigosertib is now in phase III trials for
second-line treatment of high-risk myelodysplastic syndrome
(NCT01928537 and NCT00906334) and phase II trials for first-line
treatment of low-risk myelodysplastic syndrome (NCT01584531
and NCT01904682). A phase III study of rigosertib in combination
with gemcitabine is also underway in patients with metastatic
pancreatic cancer (NCT01360853).
Volasertib. Volasertib (BI 6727) is an ATP-competitive kinase
inhibitor from the dihydropteridinone class of compounds [57].
Unlike the dual PI3K/Plk pathway inhibitor rigosertib, volasertib is a
potent and selective Plk inhibitor that did not target N50 additional
kinases tested [57]. Volasertib targets the ATP-binding pocket of
Plk1, binding to the hinge region between the amino-terminal and
the carboxyl-terminal lobes of the kinase domain through hydrogen
bonds from the dihydropteridinone core to the backbone amino and
carbonyl groups of Cys133 [57]. As residues in the ATP-binding
pocket of Plks are highly conserved, volasertib also targets Plk2 and
Plk3, although to a lesser extent than Plk1 (IC50 values of 0.87, 5, and
56 nM for Plk1, Plk2, and Plk3, respectively).
Volasertib was shown to induce the characteristic prometaphase
arrest (“Polo arrest”) associated with the inhibition of Plk1 activity
and subsequent apoptosis in a panel of human cancer cell lines in vitro
and in xenograft tumor models [57]. Importantly, the effects of
volasertib on xenograft tumors were not observed in normal intestinal
cells of mice, suggesting that volasertib may have less of an effect on
normal proliferating tissues. Volasertib was also efficacious in a
taxane-resistant xenograft model [57] and in a human AML xenograft
model [66]. In animal models, volasertib demonstrated a high volume
of distribution, which indicated good tissue penetration, a long
half-life, and good oral bioavailability [57]. These preclinical
observations are supported by early clinical trial data in numerous
studies of patients with solid tumors and AML [67–69].
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preclinical studies, volasertib demonstrated synergy with Aurora
kinase inhibition in cell lines generated from patients with relapsed
pediatric leukemia [70]. Volasertib is currently in a phase III trial in
combination with low-dose cytarabine in patients aged ≥65 years
with previously untreated AML who are ineligible for intensive
remission induction therapy (NCT01721876). Phase II trials of
volasertib in patients with various tumor types, including AML [71]
and urothelial [72] and ovarian cancers, have been completed [73],
and a phase II trial in advanced non–small cell lung cancer
(NCT00824408) is ongoing.Table 1. Small Molecule Plk1 Inhibitor Structures, Mechanisms of Action, and Preclinical Activities
Agent/Structure Mech
Rigosertib (ON 01910.Na) (benzylstyryl sulphone) Affec
Volasertib (BI 6727) (dihydropteridinone derivative) ATP-
GSK 461364 (thiophene derivative) ATP-
GW843682 (benzimidazole thiophene) ATP-
PLHS-Pmab ((2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid) Interf
functGSK461364A. GSK461364A is a selective and reversible
ATP-competitive inhibitor of Plk1 that induced growth inhibition
in a panel of human solid and peripheral blood tumor cell lines and
xenograft tumor models [58]. The cell cycle effects of GSK461364A
were dose-dependent, primarily resulting in the characteristic
prometaphase Polo arrest and subsequent apoptosis at doses of 10
to 250 nM. At higher concentrations (N250 nM), GSK461364A
induced a G2 phase arrest followed by a gradual progression into
terminal mitoses, which correlated with a decrease in apoptosis in
some cases [58]. Loss of p53 activity in human cancer cells was
associated with increased sensitivity to GSK461364A compared withanism of Action IC50
ts microtubule dynamics Plk1 = 9-10 nM
10- to 20-fold higher concentrations were
required for inhibition of Plk2 [56]
competitive inhibitor Plk1 = 0.87 nM
Plk2 = 5 nM
Plk3 = 56 nM [57]
competitive inhibitor Plk1 ≤ 0.5 nM *
Plk2 = 860 nM *
Plk3 = 1000 nM * [58]
competitive inhibitor Plk1 = 2.2 nM
Plk2 = N/A
Plk3 = 9.1 nM [59]
eres with Plk1 PBD
ions in vitro and in vivo
Not reported [60]
(continued on next page)
TABLE 1 (continued)
Agent/Structure Mechanism of Action IC50
PPG (benzotropolone-containing compound) Inhibits PBD-dependent
binding in vitro and in vivo
Plk1 = ~0.3 μM
(in glutathione S-transferase pull-down assay)
Plk2 = N/A
Plk3 = N/A [61]
Poloxin (thymoquinone derivative) Interferes with Plk1 PBD
functions in vitro and in vivo
Plk1 = 4.8 μM
Plk2 = 18.7 μM
Plk3 = 53.9 μM [62]
N/A, not applicable.
* IC
50
values for GSK461364A were determined on the basis of the intrinsic binding constant (K
i
app), which was calculated by applying the Cheng-Prusoff relationship for a competitive inhibitor (ATP K
m
app = 16 μM) to
the IC50 value obtained following a 60-minute preincubation in the presence of GSK461364A [58].
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GSK461364A was shown to increase the radiosensitivity of glioblas-
toma multiforme cells, with no effect on normal cells [75]. Clinical
activity of GSK461364A was reported in some patients with advanced
solid tumors in a phase I study [76].
CFI-400945 fumarate. CFI-400945 fumarate is a Plk4 inhibitor
discovered using a virtual screening program of ligands designed based
on a novel (E)-3-((1H-indazol-6-yl)methylene)indolin-2 struc-
ture [77]. CFI-400945 demonstrated an IC50 of 0.6 nM for Plk4,
at least two orders of magnitude higher than that observed for any
other kinases, including other Plk family members (N10 μM). In
human cancer cell lines and xenograft tumor models, CFI-400945
inhibited cell proliferation and tumor growth [42,77]. CFI-400945
was shown to suppress phosphorylation of Plk4 and histone H3,
leading to failure of centrosome clustering and formation of
multipolar spindles and resulting in cell death [42]. Interestingly,
response to Plk4 inhibition appeared to differ between breast cancer
subtypes and may be influenced by hormone receptor status (e.g., estrogen
receptor) and the presence of specific mutations (e.g., PTEN) [42].
A phase I trial in patients with advanced cancer is currently recruiting
(NCT01954316).
TKM-080301 (TKM-PLK1). TKM-080301 (TKM-PLK1) is a
lipid nanoparticle formulation of a small interfering RNA directed
against Plk1 [78,79]. In preclinical studies, TKM-080301 induced
Plk1 mRNA cleavage and silencing of Plk1 expression in human
cancer cell lines and potent antiproliferative activity in various cancer
cell lines. Antitumor activity in xenograft tumor models was also
observed [79]. Further, in vivo silencing of Plk1 expression by
TKM-080301 was detected for up to 7 to 10 days following single
administration. TKM-080301 is being evaluated in a first-in-human,
dose-escalation, phase I study in patients with advanced solid tumors
or lymphoma, which will include study of the pharmacodynamic
effects of Plk1 inhibition in patient biopsy samples [78].
Plk Inhibitors in Preclinical Development
GW843682. GW843682, a selective thiophene benzimidazole
ATP-competitive inhibitor of Plk1 (IC50 of 2.2 nM) and Plk3 (IC50of 9.1 nM), demonstrated N100-fold greater selectivity for Plk1
compared with other non-Plk kinases tested [59]. GW843682
inhibited the proliferation of a variety of human solid tumor cell lines,
demonstrating a transient G2/M arrest and mitotic spindle defects
and resulting in apoptosis. While GW843682 also induced a G2/M
arrest in normal human diploid fibroblasts, little apoptosis was
observed [59].
Plk1 PBD inhibitors (PLHS-Pmab, purpurogallin, and poloxin). Structural
studies of Plk1 suggest that the two polo-boxmotifs of the PBD contain
identical β6α folds (consisting of a six-stranded antiparallel β-sheet and
an α-helix), forming a heterodimeric phosphopeptide-binding module
[80]. The Lee laboratory showed that a phosphopeptide, PLHSpT,
derived from the T78 motif of the PBD-binding centromere protein
PBIP1 [16], binds to the PBD in a cleft formed between the two
polo-box motifs through direct hydrogen bonding and inhibits the
interaction between the PBD and its binding targets [60]. On the basis
of these findings, a nonhydrolyzable p-Thr78 mimetic peptide
(PLHS-Pmab) was synthesized and its activity was assessed in HeLa
cells. In glutathione S-transferase pull-down assays, PLHS-Pmab
interacted with Plk1 but not Plk2 or Plk3 [60]. Similar to the
phenotype observed with loss of PBD function, cells treated with
PLHS-Pmab demonstrated a chromosome congression defect followed
by mitotic catastrophe. Further, reduced Plk1 localization at the
centrosomes and kinetochores was observed [60].
In addition to PBD-binding phosphopeptides, the compounds
purpurogallin (PPG) and poloxin have been described as small,
drug-like Plk1 PBD inhibitors [81]. However, these compounds
demonstrate different PBD-binding properties and are associated
with distinct cellular phenotypes. PPG, a natural benzotropolone
compound extracted from nutgalls, was found in a high-throughput
screening of natural products to identify inhibitors of PBD-depen-
dent binding [61]. Structurally, PPG was proposed to fill the SpT
pocket of the PBD through π-π stacking, electrostatic, and hydrogen
bonding interactions [81]. PPG was shown to inhibit PBD binding of
Plk1 and Plk2 but not Plk3 [61]. PPG inhibited PBD-dependent
binding of Plk1 in vitro and in HeLa cells, decreasing centrosomal
and kinetochore localization of Plk1 [61]. Although PPG did not
Translational Oncology Vol. 8, No. 3, 2015 Targeting Polo-Like Kinases Liu 193appear to impair the formation of bipolar spindles, chromosome
alignment at metaphase plates was perturbed, which activated the spindle
assembly checkpoint pathway and prolonged mitotic progression.
Poloxin is a synthetic derivative of thymoquinone, a constituent of
black seed (Nigella sativa) known for its antineoplastic activity [62].
Unlike PPG, poloxin does not appear to target the SpT pocket of the
PBD but may fill a different site within the PBD through covalent
bonding [81]. Poloxin inhibits the PBD of Plk1 in vitro (IC50 of
4.8 μM) and Plk2 and Plk3 to a slightly lesser extent (IC50 of 18.7
and 53.9 μM, respectively). Inhibition of Plk1 by poloxin results in
Plk1 mislocalization, chromosomal defects, mitotic arrest, and
apoptosis in cancer cell lines and xenograft tumor models [62,82].
There has been some concern that poloxin causes unacceptable levels
of cytotoxicity, and a critical assessment of the efficacy and safety of
these PBD inhibitors should be conducted [3].
Conclusion
Plks appear to be relevant and feasible targets for cancer treatment,
and Plk inhibitors are currently under investigation to determine their
efficacy and safety profiles in diverse tumor types. Preclinical studies
have demonstrated a particular sensitivity to Plk1 inhibition in
human cancer cells harboring specific genetic abnormalities,
including mutations in p53, Ras, and PTEN [43,44,54]. These
studies provide a rationale for potential patient selection in the clinic,
as patients with tumors showing these mutations may particularly
benefit from Plk1 inhibitor therapy. In addition to exploring genetic
biomarkers for patient selection, there is a critical need for further
evaluation of pharmacodynamic endpoints and functional biomarkers
of response to Plk inhibition. Despite the existence of many
downstream targets of Plk1 activity, there are currently no defined
biomarkers of response developed for clinical use [83]. The
identification and development of biomarkers associated with
sensitivity and clinical response to Plk inhibitors could not only
improve patient selection and provide a means to monitor treatment
efficacy but also open the door to new therapeutic combination strategies.
In addition to the current focus on Plk1, a greater understanding of the
roles of Plk2 and Plk3 in cancer development is needed. If they are truly
tumor suppressors, partial inhibition by Plk1 inhibitors could support
long-termmalignant progression [3]. For thosePlks affectedbymethylation
events, such as Plk2 [36,37], it has been postulated that drugs used to
reverse hypermethylation may represent an effective strategy to restore Plk
tumor suppressive activities, particularly in combination treatments [50].
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